Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called Peripheral T-Cell Lymphoma (PTCL), which is a rare and aggressive form of non-Hodgkin lymphoma. The study is specifically for patients whose cancer has returned or has not responded to previous treatments. The trial will test a new treatment approach using a medication called Lacutamab, also known by its code name IPH4102, in combination with two chemotherapy drugs, Gemcitabine and Oxaliplatin, collectively referred to as GemOx. The purpose of the study is to evaluate how effective Lacutamab is when used with GemOx compared to using GemOx alone.

Participants in the study will be randomly assigned to receive either the combination of Lacutamab with GemOx or GemOx alone. Lacutamab is a type of protein-based treatment known as a monoclonal antibody, which is designed to target specific cancer cells. Gemcitabine and Oxaliplatin are chemotherapy drugs that work by stopping the growth of cancer cells. The treatment will be given through an intravenous infusion, which means it will be administered directly into the bloodstream. The study will monitor the participants over a period to see how the cancer responds to the treatment and to assess the safety and potential side effects of the medications.

The trial aims to provide valuable information on whether adding Lacutamab to the standard GemOx treatment can improve outcomes for patients with relapsed or refractory Peripheral T-Cell Lymphoma. This study is important for understanding new ways to treat this challenging disease and may help in developing more effective treatment options in the future.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization

    Upon joining the study, the patient is randomly assigned to one of two groups. One group receives a combination of lacutamab with gemcitabine and oxaliplatin (GemOx), while the other group receives GemOx alone.

    Randomization ensures that each patient has an equal chance of being assigned to either treatment group.

  2. Step 2

    Treatment administration

    The patient receives the assigned treatment intravenously. This involves the administration of medications directly into a vein.

    For those in the lacutamab with GemOx group, lacutamab is administered alongside gemcitabine and oxaliplatin. The specific dosage and frequency are determined by the study protocol.

  3. Step 3

    Treatment cycle

    The treatment is given in cycles. Each cycle consists of a period of treatment followed by a period of rest to allow the body to recover.

    The duration of each cycle and the number of cycles are specified in the study protocol.

  4. Step 4

    Monitoring and assessments

    Throughout the study, the patient's health and response to treatment are closely monitored. This includes regular medical assessments and imaging tests.

    The purpose of these assessments is to evaluate the effectiveness of the treatment and to monitor for any side effects.

  5. Step 5

    Maintenance phase

    For patients receiving lacutamab, a maintenance phase follows the initial treatment cycles. During this phase, lacutamab is administered to help maintain the response to treatment.

    The frequency and duration of the maintenance phase are determined by the study protocol.

  6. Step 6

    End of study participation

    The patient's participation in the study concludes after completing the treatment cycles and maintenance phase, or if certain criteria are met, such as disease progression or the need for additional unplanned treatments.

    At the end of the study, final assessments are conducted to gather comprehensive data on the patient's response to the treatment.

Who can join the trial?

16 criteria

  • The patient must have a type of cancer called **Peripheral T-Cell Lymphoma (PTCL)** that has come back or not responded to treatment.
  • The patient's cancer cells must show a specific marker called **KIR3DL2** in at least 1% of the cells, confirmed by a special test.
  • The patient must be able to perform daily activities with an **ECOG performance status** of 0 to 3 before starting any pre-treatment, and 0 to 2 before being randomly assigned to a treatment group. This is a scale that measures how well a patient can carry out daily activities.
  • The patient should have a life expectancy of at least 3 months.
  • Women who can have children must agree to use a highly effective birth control method from the start of the study, during any breaks in treatment, and for 9 months after the last treatment. They must also have a negative pregnancy test before starting the study.
  • Male patients and their female partners who can have children must agree to use two reliable forms of birth control (a condom for males and a hormonal method for partners) from the start of the study, during any breaks in treatment, and for 9 months after the last treatment.
  • The patient must be covered by a social security system in France.
  • The patient must understand and speak one of the official languages of the country where the study is conducted.
  • The patient must have a confirmed diagnosis of PTCL based on a biopsy, which is a procedure to remove a small piece of tissue for testing. The types of PTCL include PTCL-NOS, PTCL-TFH, ALCL, ATL, HSTL, EATL, MEITL, NKT, and ANKL.
  • For patients with **ALCL** (a type of PTCL), they must have been previously treated with a drug called **brentuximab vedotin**.
  • The patient must have had at least one previous treatment for PTCL that involved chemotherapy, with no required waiting period after the last treatment.
  • The patient can have had a maximum of two previous treatments, including a procedure called **autologous stem cell transplantation (ASCT)**, which is a treatment that uses the patient's own stem cells.
  • The patient must have a tumor that can be measured in two dimensions, with at least one tumor or lymph node that is 1.5 cm or larger, as seen on a **CT scan**, which is an imaging test.
  • The patient must sign a written consent form to be screened for the KIR3DL2 marker.
  • The patient must sign a written consent form to participate in the study.
  • The patient must be 18 years or older, with no upper age limit.

Who cannot join the trial?

6 criteria

  • Patients who have not experienced a return or worsening of their condition after previous treatment.
  • Patients who do not have a type of cancer called **Peripheral T-Cell Lymphoma**.
  • Patients who do not have a specific protein called **KIR3DL2** on their cancer cells.
  • Patients who are not within the specified age range for the study.
  • Patients who are part of a vulnerable population, which means they might need special protection or care.
  • Patients who are not able to receive the specific treatment plan outlined in the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Lacutamab

    is an investigational medication being studied for its potential to treat certain types of T-cell lymphoma. It is being evaluated for its ability to help control the disease in patients who have not responded to previous treatments or whose disease has returned. In this trial, Lacutamab is used in combination with other cancer treatments to see if it can improve outcomes for patients.

  • Gemcitabine

    is a chemotherapy medication used to treat various types of cancer, including lymphoma. It works by interfering with the growth of cancer cells, slowing or stopping their spread in the body. In this study, Gemcitabine is used as part of a combination therapy to treat patients with relapsed or refractory T-cell lymphoma.

  • Oxaliplatin

    is another chemotherapy drug that is used to treat cancer. It is often combined with other medications to enhance its effectiveness. Oxaliplatin works by damaging the DNA of cancer cells, which can lead to their death. In this clinical trial, Oxaliplatin is used alongside Gemcitabine to treat patients with certain types of T-cell lymphoma.

What is already known about the treatment

Lacutamab – Lacutamab is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating relapsed or refractory peripheral T-cell lymphoma. It is not yet widely used in standard medical practice but is gaining attention in medical literature for its potential benefits. The main therapeutic indication for Lacutamab is in patients with specific types of T-cell lymphoma, particularly those expressing the KIR3DL2 marker. At the molecular level, Lacutamab works by targeting and binding to the KIR3DL2 protein on the surface of cancer cells, which may help the immune system recognize and destroy these cells. It is classified as a monoclonal antibody in pharmacology.

Investigated diseases

Peripheral T-cell Lymphoma – Peripheral T-cell lymphoma is a group of aggressive lymphomas that originate from mature T-cells. It is characterized by the uncontrolled growth of T-cells, which are a type of white blood cell. The disease often presents with symptoms such as swollen lymph nodes, fever, and weight loss. It can affect various parts of the body, including the lymph nodes, liver, and spleen. The progression of the disease can vary, with some subtypes being more aggressive than others. Treatment typically involves chemotherapy, but the disease can be challenging to manage due to its aggressive nature.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-513252-15-00Protocol codeKILTEstimated enrolment56 patientsSponsorLysarc

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).